Charles Lu

17.0k total citations · 2 hit papers
100 papers, 8.3k citations indexed

About

Charles Lu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Otorhinolaryngology. According to data from OpenAlex, Charles Lu has authored 100 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Pulmonary and Respiratory Medicine, 46 papers in Oncology and 24 papers in Otorhinolaryngology. Recurrent topics in Charles Lu's work include Lung Cancer Treatments and Mutations (32 papers), Head and Neck Cancer Studies (24 papers) and Lung Cancer Diagnosis and Treatment (21 papers). Charles Lu is often cited by papers focused on Lung Cancer Treatments and Mutations (32 papers), Head and Neck Cancer Studies (24 papers) and Lung Cancer Diagnosis and Treatment (21 papers). Charles Lu collaborates with scholars based in United States, China and Canada. Charles Lu's co-authors include David I. Rosenthal, Randal S. Weber, Richard C. Jordan, Jonathan Harris, William H. Westra, Kevin P. Redmond, Maura L. Gillison, Christine H. Chung, K. Kian Ang and Phuc Félix Nguyen‐Tan and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Charles Lu

95 papers receiving 8.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer

2010 4.8k citations Randal S. Weber, David I. Rosenthal et al. profile →
Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non–Small-Cell Lung Cancer

2018 214 citations Zhongxing Liao, J. Jack Lee et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Charles Lu United States	32	4.2k	3.1k	2.7k	2.5k	1.5k	100	8.3k
Francis P. Worden United States	49	3.5k 0.8×	3.5k 1.1×	2.3k 0.8×	3.1k 1.2×	1.7k 1.1×	257	9.1k
Erich M. Sturgis United States	56	4.9k 1.2×	4.0k 1.3×	2.5k 0.9×	3.2k 1.3×	3.1k 2.1×	305	11.1k
Hisham Mehanna United Kingdom	43	3.2k 0.8×	1.9k 0.6×	1.6k 0.6×	2.2k 0.9×	1.0k 0.7×	217	6.7k
Merrill S. Kies United States	57	5.7k 1.4×	7.3k 2.3×	5.3k 2.0×	5.2k 2.0×	2.7k 1.8×	178	14.6k
David J. Adelstein United States	51	5.1k 1.2×	3.3k 1.1×	4.6k 1.7×	5.0k 2.0×	727 0.5×	257	10.2k
Athanassios Argiris United States	47	3.5k 0.8×	4.2k 1.4×	2.8k 1.0×	2.2k 0.9×	2.7k 1.8×	243	8.9k
Lars Bastholt Denmark	42	1.1k 0.3×	4.2k 1.3×	1.7k 0.6×	1.3k 0.5×	1.8k 1.2×	183	8.3k
Vivian Weinberg United States	45	1.2k 0.3×	2.2k 0.7×	3.4k 1.2×	2.1k 0.8×	895 0.6×	173	7.8k
Eric Winquist Canada	49	1.3k 0.3×	4.2k 1.4×	3.1k 1.1×	3.5k 1.4×	2.1k 1.4×	291	9.3k
Daniel J. Haraf United States	49	4.8k 1.1×	3.3k 1.1×	3.3k 1.2×	3.4k 1.4×	891 0.6×	196	8.1k

Countries citing papers authored by Charles Lu

Since Specialization

Citations

This map shows the geographic impact of Charles Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Lu more than expected).

Fields of papers citing papers by Charles Lu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Lu. The network helps show where Charles Lu may publish in the future.

Co-authorship network of co-authors of Charles Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Charles Lu. A scholar is included among the top collaborators of Charles Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles Lu. Charles Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dadu, Ramona, Naifa L. Busaidy, Renata Ferrarotto, et al.. (2024). Cobimetinib plus atezolizumab for RAS and NF1/2-mutated poorly differentiated thyroid carcinoma.. Journal of Clinical Oncology. 42(16_suppl). 6106–6106. 3 indexed citations

Wang, Jennifer, Xu Li, Maitrayee Goswami, et al.. (2022). Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma. JCO Precision Oncology. 6(6). e2100504–e2100504. 45 indexed citations

Aggarwal, Puja, Katherine A. Hutcheson, Adam S. Garden, et al.. (2021). Determinants of patient‐reported xerostomia among long‐term oropharyngeal cancer survivors. Cancer. 127(23). 4470–4480. 18 indexed citations

Ferrarotto, Renata, Luana Guimarães de Sousa, Yun Qing, et al.. (2021). Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial. Advances in Therapy. 38(8). 4581–4591. 9 indexed citations

Tam, Samantha, Xiaoning Luo, Bonnie S. Glisson, et al.. (2021). Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. Head & Neck. 43(5). 1592–1603. 3 indexed citations

Gjyshi, Olsi, Ting Xu, Adnan Elhammali, et al.. (2020). Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. Journal of Thoracic Oncology. 16(2). 269–277. 28 indexed citations

Wang, Jennifer, Mark Zafereo, Ramona Dadu, et al.. (2019). Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAF ^V600E -Mutated Anaplastic Thyroid Carcinoma. Thyroid. 29(8). 1036–1043. 150 indexed citations

Gunn, G. Brandon, Clifton D. Fuller, David I. Rosenthal, et al.. (2019). Xerostomia Impacts Dysgeusia in Oropharyngeal Cancer Patients Treated with Proton Therapy. International Journal of Radiation Oncology*Biology*Physics. 105(1). E414–E415. 1 indexed citations

Wang, Jennifer, Gilbert J. Cote, Mark Zafereo, et al.. (2018). Facilitating rapid precision oncology in anaplastic thyroid cancer: Clinical implications of next generation sequencing (NGS) mutation testing and impact on survival.. Journal of Clinical Oncology. 36(15_suppl). 6023–6023.

10.

Reyes‐Gibby, Cielito C., Stephanie C. Melkonian, Ehab Y. Hanna, et al.. (2017). Cohort study of oncologic emergencies in patients with head and neck cancer. Head & Neck. 39(6). 1195–1204. 12 indexed citations

11.

Yue, Jinbo, Ting Xu, Tinsu Pan, et al.. (2015). The Predictive Value of Serial 18F-FDG PET/CT for Recurrence and Survival of Locally Advanced Non-Small Cell Lung Cancer After Concurrent Chemoradiation Therapy. International Journal of Radiation Oncology*Biology*Physics. 93(3). E430–E431. 1 indexed citations

12.

Nguyen, Quynh-Nhu, Ritsuko Komaki, Lawrence B. Levy, et al.. (2015). Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II–III inoperable non-small cell lung cancer. Radiotherapy and Oncology. 115(3). 367–372. 77 indexed citations

13.

Gunn, G. Brandon, Adam S. Garden, Clifton D. Fuller, et al.. (2015). Favorable patient reported outcomes following IMRT for early carcinomas of the tonsillar fossa: Results from a symptom assessment study. Radiotherapy and Oncology. 117(1). 132–138. 17 indexed citations

14.

Fagundes, Christopher P., Desirée Jones, Elisabeth G. Vichaya, Charles Lu, & Charles S. Cleeland. (2014). Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status Do Not Make a Difference. Journal of Thoracic Oncology. 9(10). 1459–1463. 22 indexed citations

15.

Sosa, Julie Ann, Rossella Elisei, Barbara Jarząb, et al.. (2013). Randomized Safety and Efficacy Study of Fosbretabulin with Paclitaxel/Carboplatin Against Anaplastic Thyroid Carcinoma. Thyroid. 24(2). 232–240. 116 indexed citations

16.

Chen, Xing, Ivan P. Gorlov, Binwu Ying, et al.. (2012). Initial Medical Attention on Patients with Early-Stage Non-Small Cell Lung Cancer. PLoS ONE. 7(3). e32644–e32644. 6 indexed citations

17.

Cleeland, Charles S., Tito R. Mendoza, Xin Shelley Wang, et al.. (2011). Levels of Symptom Burden During Chemotherapy for Advanced Lung Cancer: Differences Between Public Hospitals and a Tertiary Cancer Center. Journal of Clinical Oncology. 29(21). 2859–2865. 37 indexed citations

18.

Jiang, Zhi-Qin, Kunyu Yang, Ritsuko Komaki, et al.. (2011). Long-Term Clinical Outcome of Intensity-Modulated Radiotherapy for Inoperable Non-Small Cell Lung Cancer: The MD Anderson Experience. International Journal of Radiation Oncology*Biology*Physics. 83(1). 332–339. 119 indexed citations

19.

Wu, Xifeng, Charles Lu, Yuanqing Ye, et al.. (2008). Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenetics and Genomics. 18(11). 955–965. 41 indexed citations

20.

Kindler, Hedy L., Theodore Karrison, David R. Gandara, et al.. (2007). C5-06: Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients with malignant mesothelioma. Journal of Thoracic Oncology. 2(8). S374–S374. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact